{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:24:58Z","timestamp":1789885498638,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003704","name":"KRICT","doi-asserted-by":"publisher","award":["KK1603"],"award-info":[{"award-number":["KK1603"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003669","name":"KCDC","doi-asserted-by":"publisher","award":["2015-ER4808-00"],"award-info":[{"award-number":["2015-ER4808-00"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.antiviral.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T07:15:48Z","timestamp":1487315748000},"page":"101-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"special_numbering":"C","title":["Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL Pro inhibitors"],"prefix":"10.1016","volume":"141","author":[{"given":"Vathan","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-214X","authenticated-orcid":false,"given":"Jiun-Jie","family":"Shie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun Bon","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonsaeng","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Young","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5235-7421","authenticated-orcid":false,"given":"Kai-Fa","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meehyein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Huang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.02.007_bib1","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1021\/jm200870n","article-title":"Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors","volume":"54","author":"Akaji","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib2","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1016\/j.bmc.2008.09.057","article-title":"Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant","volume":"16","author":"Akaji","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CL(pro)) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.02.007_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/fvl.11.33","article-title":"Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy","volume":"6","author":"Barnard","year":"2011","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2017.02.007_bib5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jit123","article-title":"Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC\/2012: implications for disease pathogenesis and clinical manifestation","volume":"207","author":"Chan","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2017.02.007_bib6","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in\u00a0vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-\u03b1 treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.02.007_bib7","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.02.007_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1074\/jbc.M310875200","article-title":"Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase","volume":"279","author":"Fan","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib9","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1021\/jm050548m","article-title":"Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors","volume":"48","author":"Ghosh","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.antiviral.2013.08.015","article-title":"From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses","volume":"100","author":"Hilgenfeld","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.02.007_bib11","doi-asserted-by":"crossref","first-page":"31257","DOI":"10.1074\/jbc.M502577200","article-title":"Mechanism of the maturation process of SARS-CoV 3CL protease","volume":"280","author":"Hsu","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib12","doi-asserted-by":"crossref","first-page":"e0144865","DOI":"10.1371\/journal.pone.0144865","article-title":"Critical assessment of the important residues involved in the dimerization and catalysis of MERS coronavirus main protease","volume":"10","author":"Ho","year":"2015","journal-title":"PLos One"},{"key":"10.1016\/j.antiviral.2017.02.007_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bpc.2016.09.005","article-title":"Susceptibility of inhibitors against 3C protease of coxsackievirus A16 and enterovirus A71 causing hand, foot and mouth disease: a molecular dynamics study","volume":"219","author":"Jetsadawisut","year":"2016","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.antiviral.2013.11.004","article-title":"Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors","volume":"101","author":"Kilianski","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.02.007_bib15","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1128\/JVI.03688-14","article-title":"Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses","volume":"89","author":"Kim","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.007_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543776.2013.823159","article-title":"Anti-SARS coronavirus agents: a patent review (2008-present)","volume":"23","author":"Kumar","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.antiviral.2017.02.007_bib17","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.bmc.2016.05.013","article-title":"Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors","volume":"24","author":"Kumar","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cben.201400031","article-title":"Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus","volume":"2","author":"Kuo","year":"2015","journal-title":"ChemBioEng Rev."},{"key":"10.1016\/j.antiviral.2017.02.007_bib19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2004.04.098","article-title":"Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate","volume":"318","author":"Kuo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2017.02.007_bib20","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1016\/j.bmc.2008.06.015","article-title":"Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents","volume":"16","author":"Kuo","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib21","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1074\/jbc.M807947200","article-title":"Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds","volume":"284","author":"Lee","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib22","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","article-title":"Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes","volume":"96","author":"Matthews","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2017.02.007_bib23","first-page":"1102","article-title":"Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity","volume":"D71","author":"Needle","year":"2015","journal-title":"Acta Cryst."},{"key":"10.1016\/j.antiviral.2017.02.007_bib24","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1042\/BST0391371","article-title":"Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery","volume":"39","author":"Ramajayam","year":"2011","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.antiviral.2017.02.007_bib26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1085952","article-title":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome","volume":"300","author":"Rota","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2017.02.007_bib27","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1016\/j.bmc.2005.05.065","article-title":"Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic \u03b1,\u03b2-unsaturated esters","volume":"13","author":"Shie","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib28","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1016\/j.bmc.2015.06.039","article-title":"Targeting zoonotic viruses: structure-based inhibition of the 3C-like protease from bat coronavirus HKU4-The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS)","volume":"23","author":"St John","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejmech.2013.07.037","article-title":"Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies","volume":"68","author":"Thanigaimalai","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib30","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1128\/JVI.75.14.6676-6681.2001","article-title":"Viral replicase gene products suffice for coronavirus discontinuous transcription","volume":"75","author":"Thiel","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2017.02.007_bib31","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","article-title":"Mechanisms and enzymes involved in SARS coronavirus genome expression","volume":"84","author":"Thiel","year":"2003","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.02.007_bib32","doi-asserted-by":"crossref","first-page":"19403","DOI":"10.1074\/jbc.M115.651463","article-title":"Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals","volume":"290","author":"Tomar","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/13543770802600698","article-title":"Therapies for coronaviruses. Part 2: inhibitors of intracellular life cycle","volume":"19","author":"Tong","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.antiviral.2017.02.007_bib34","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bmj.1.5448.1467","article-title":"Cultivation of a novel type of common-cold virus in organ cultures","volume":"1","author":"Tyrrell","year":"1965","journal-title":"Br. Med. J."},{"key":"10.1016\/j.antiviral.2017.02.007_bib35","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1021\/jm980071x","article-title":"Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements","volume":"42","author":"Webber","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib36","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2017.02.007_bib37","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.antiviral.2017.02.007_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1574891X113089990017","article-title":"Recent developments on coronavirus main protease\/3C like protease inhibitors","volume":"8","author":"Zhao","year":"2013","journal-title":"Recent Pat. Antiinfect. Drug Discov."},{"key":"10.1016\/j.antiviral.2017.02.007_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.08.001","article-title":"Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease","volume":"92","author":"Zhu","year":"2011","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216305083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216305083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T03:23:57Z","timestamp":1536031437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216305083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":39,"alternative-id":["S0166354216305083"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.02.007","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}